The FDA granted the first pediatric indication for an implantable cardiac monitor. The Linq II can be used in pediatric patients over the age of 2 for up to 4.5 years of long-term, continuous monitoring.
The Pascal transcatheter mitral valve repair system. Similar to the latest version of the MitraClip, the Pascal can operate each leaflet independently to grasp the mitral valve leaflets.
Comparison between transcatheter edge-to-edge repair (TEER) devices found Pascal was non-inferior compared with MitraClip in the CLASP IID pivotal trial.
Use of ultrasound to guide needles used for femoral vascular access used in cath lab procedures is believed to help reduce bleeding and vascular complications. But the UNIVERSAL trial at TCT 2022 showed no difference. Image courtesy of Sonosite
The UNIVERSAL Trial, one of the largest multicenter randomized trials comparing ultrasound with fluoroscopic guidance vs. fluoroscopic guidance alone, found there was no reduction in major vascular access complications.
Positive data was presented on the first-generation Symplicity (left) long-term outcomes data, and from the Recor ultrasound renal denervation system (right) pivotal trial at TCT 2022.
Results from the Medtronic SYMPLICITY HTN-3 trial long-term results and the pivotal RADIANCE II trial for the Recor ultrasound renal denervation system lowered blood pressure effectively in drug-resistant patients.
The PROTECTED TAVR results presented at TCT 2022 resulted in a mix of reactions. For some cardiologists, the slight reduction in the risk of a disabling stroke after TAVR is a positive result. For others, it was simply not enough.
A new study shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in CT and PET/CT images than physicians.
This is the second FDA-cleared transcatheter repair device for the mitral valve. Data from pivotal trial comparing Pascal vs. MitraClip will be presented at TCT 2022.
Joao Cavalcante, MD, director, cardiac MRI and structural CT labs, Minneapolis Heart Institute, discusses the use of cardiac CT imaging to plan and guide structural heart procedures.
According to a new analysis from MedAxiom, an American College of Cardiology company, cardiologist compensation has nearly returned to where it was before the COVID-19 pandemic. The detailed report also examined new patient visits, cardiac imaging utilization and much more.
![A study published this week in the Journal of the American College of Cardiology (JACC): Cardiovascular Imaging shows artificial intelligence (AI) algorithms can more rapidly and objectively determine calcium scores in computed tomographic (CT) and positron emission tomographic (PET) images than physicians.[1] The AI also performed well when the images were obtained from very-low-radiation CT attenuation scans. https://doi.org/10.1016/j.jcmg.2022.06.006](/sites/default/files/styles/top_stories/public/2022-09/ai_cac_calcium_score_reading_study_for_pet_ct.jpg.webp?itok=GoiezUxV)
